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Abstract
Aim To present results, 1 year postimplementation at pri-
mary care level, of an integrated diabetes care programme
including systemic changes, education, registry (clinical,
metabolic, and therapeutic indicators), and disease man-
agement (DIAPREM).
Methods We randomly selected and trained 15 physicians
and 15 nurses from primary care units of La Matanza
County (intervention—IG) and another 15 physicians/nur-
ses to participate as controls (control—CG). Each physi-
cian–nurse team controlled and followed up 10 patients
with type 2 diabetes for 1 year; both groups used structured
medical records. Patients in IG had quarterly clinical
appointments, whereas those in CG received traditional
care. Statistical data analysis included parametric/
nonparametric tests according to data distribution profile
and Chi-squared test for proportions.
Results After 12 months, the dropout rate was significantly
lower in IG than in CG. Whereas in IG HbA1c, blood
pressure and lipid profile levels significantly decreased, no
changes were recorded in CG. Drug prescriptions showed
no significant changes in IG except a decrease in oral
monotherapy.
Conclusions DIAPREM is an expedient and simple mul-
tistrategic model to implement at the primary care level in
order to decrease patient dropout and improve control and
treatment adherence, and quality of care of people with
diabetes.
Keywords Quality of care Therapeutic education 
Medical data registry  Diabetes primary care  Treatment
adherence  Disease managementManaged by Massimo Porta.
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Despite available evidence supporting the concept that
appropriate control of blood glucose and associated car-
diovascular risk factors (CVRFs) can reduce diabetes
complications—the major cause of morbidity, mortality,
and costs of the disease [1–7]—these preventive strategies
have not been widely incorporated into clinical practice
[8]. Consequently, care received by people with diabetes is
frequently far from optimal [9–15].
Several factors contribute to this disappointing situation
such as a) inadequate knowledge and experience of
healthcare providers [12], b) inadequate provider attitude
towards application of guidelines [16, 17], c) limited
patient access to care, d) poor adherence with self-care and
treatment, and e) scant attention given patient education
[8, 17]. Lack of continuous evaluation and systematic
registry of medical outcomes with concomitant treatment
adjustments close the vicious circle that leads to poor care
outcomes [9, 11, 18]. Therefore, inappropriate control/
treatment is the final common path leading to the high
morbimortality of the disease.
Effective models of diabetes care which include sys-
temic changes and patient and/or physician education help
to overcome most of the above-mentioned problems. Sys-
temic changes most widely implemented included provi-
sion of specific care guidelines and reminders, improved
access to care by reduction in financial/administrative
barriers to care, and patient/provider feedback to monitor
care outcomes. Indeed, a review of educational interven-
tions in disease management programmes of chronic dis-
eases, including diabetes, concluded that most programmes
directed at providers and patients improved care outcomes
[19]).
In Argentina, there are three health sectors (public
health, social security, and private). The social security and
private sectors cover around 48 and 10% of the population,
respectively, and the extent of health coverage is deter-
mined by law in the Mandatory Medical Program (PMO).
The public health sector provides universal access to free
health care to almost half of the population (mostly
unemployed and low-income population not insured by
social security or private sector) through primary care units
(PCU) and public hospitals. PCUs include different types
of disease management programmes for ambulatory treat-
ment of chronic diseases such as diabetes, providing a free
supply of drugs such as human insulin, some oral drugs,
and a limited number of strips to self-monitor blood glu-
cose (SMBG).
We attempted to improve quality of diabetes care at the
primary care level and consequently improve treatment
outcomes by implementing at that level of the public health
sector, an integrated diabetes care programme that includes
systemic changes, education, registry (clinical, metabolic,
and therapeutic indicators), education (physicians and nur-
ses), and disease management (DIAPREM: DIAbetes Pri-
mary care, Registry, Education and Management) [20].
Here, we describe the clinical and metabolic outcomes after a
1-year follow-up of patients in the intervention group,
comparing them to those who received customary care.
Methods
Study design
Detailed description of the DIAPREM strategy has been
already reported [20]. Consequently, we now briefly
describe its background and contents.
Argentina has 40,117,096 inhabitants (2010 National
Census), and 39% of them live in the province of Buenos
Aires, of whom 1,775,816 (11%) live in La Matanza
County. According to the prevalence defined by the 2009
National Risk Factors Survey [21], our diabetes population
is around 2,892,000 people; only about half of them know
they have the disease (1,445,973); 70% of those diagnosed
are in regular treatment (1,012,181). Half of this population
receives free care from the public health system (506,091
people). Of this diabetes population, 4.43% lives in one
area (La Matanza) of the city suburbs in the province of
Buenos Aires, a low-income population with 34% has
unsatisfied basic needs, and only 40% of people have
completed their primary education.
Figure 1 shows the DIAPREM design. Of the 40 pri-
mary care units (PCU) of La Matanza Health Secretariat,
we randomly selected 30 physicians and 30 nurses. Of
those, 15 were randomly selected to be trained (IG group),
and another group of 15 physicians and nurses from
another 15 PCUs were also randomly selected and used as
controls (CG group).
Rather than using restrictive patient selection criteria,
our criterion was for the patient sample to represent com-
mon daily practice in the study area. For this purpose, each
physician–nurse team took care of and followed up 10
patients: adults of both genders with type 2 diabetes (T2D)
for 1 year; each patient was required to attend clinical
appointments at least every 3 months (150 people with
T2D in the CG and 150 people in the IG). People with
expected short survival (cancer or terminal conditions),
different types of addictions or psychiatric disorders, were
excluded from the selection.
During the recruitment phase, we had several meetings
with local coordinators and authorities from participating




activities, timetable, and methodology selected for the
study.
Main outcomes
Changes in HbA1C from baseline to the end of the study
were considered the primary outcome variable. Other rel-
evant outcomes were considered secondary: the proportion
of patients that attained goals such as HbA1c\ 7.0%,
glycaemia\ 100 mg/dL, blood pressure\ 130/80 mmHg,
cholesterol\ 200 mg/dL, and triglycerides\ 150 mg/dL.
Statistical power and sample size
Considering 1.7% the standard deviation of change in
HbA1c, with a 5% level of significance and 80% power, we
needed 93 patients in each group to detect a decrease of
0.5% in the main outcome. Thereafter, we chose to
increase the sample size by 50% at the first stage, assuming
this would be the rate of dropout or failure to follow-up.
This totalled 140 patients for each group. Finally, for that
purpose, we decided to recruit at least 10 patients per
physician–nurse pair.
Consequently, the programme started with a sample size
of 157 patients for CG and 154 for the IG.
Interventions
Diabetes training course for physicians Physicians in the
IG attended an online course with 14 compulsory and 12
optional modules, plus 8 h of practical activities completed
at a national reference centre. This course was released
through the School of Medicine of the National University
of La Plata (Argentina) and Indiana University (USA).
Each participant also received a manual with all the
algorithms for diagnosis, control, and treatment of T2D
included in the modules [22]. Physicians in the CG did not
receive this training.
Nurse education Nurses in the IG attended in person a
5-day full-time intensive theoretical and practical course
given at the Bernardo A. Houssay Center (La Plata,
Argentina) which also included practical activities in the
teaching hospital of the School of Medicine of the National
University of La Plata.
Patient follow-up and call centre activities Participants
in the IG were seen every three months in a programmed
visit; to decrease dropouts, the call centre called them by
telephone to remind them of their next appointment. Also,
once a year, the call centre gave each patient an appoint-
ment for cardiovascular and ophthalmological controls
done at the hospital at the same morning. In this way, we
tried to facilitate attendance to these controls and minimize
the number of work days missed.
Data registry
We used a structured registry form developed and validated
by our group (QUALIDIAB) [10] to collect patients’
clinical, biochemical, educational, and therapeutic data
previous to and after 6 and 12 months of the DIAPREM
implementation. QUALIDIAB registry includes clinical,
metabolic, and associated CVRF indicators, degree of
diabetes education, hospitalization events, and type of
treatment prescriptions. These forms were filled in by the







physicians and nurses in both groups who were trained
previously to record data properly on the data registry. The
QUALIDIAB system also includes a feedback mechanism:
physicians and nurses received a form from each patient
comparing treatment target values and current values of
different clinical and metabolic indicators (HbA1c and the
other CVRF); if the patient did not achieve target values,
the form suggests the issues the care team should focus on
in particular. In this study, feedbacks were not available to
the CG.
Data analysis
We used the Statistical Package for Social Sciences version
15 (SPSS Inc, Chicago, IL, USA). Descriptive statistics are
presented as percentages and mean ± standard deviation
(SD). Group comparisons for continuous variables were
made by a parametric or nonparametric test depending on
the data distribution profile. The Chi-squared test was used
to estimate differences between proportions. Significance
was established at p B 0.05.
Ethical issues
The study protocol was analysed and approved by the
Bioethical Committee of the National University of La
Plata. The study was developed according to the Good
Practice Recommendations (International Harmonisation
Conference) and the ethical guidelines of the Helsinki
Declaration. All subjects gave their written informed con-
sent to participate in the study, and it was signed before
their inclusion in the study cohort. At the end of the study,
the 15 physicians and 15 nurses who were initially in the
control group will receive the same training courses
received previously by the intervention group.
Results
Dropouts
During the 1-year follow-up, patients who dropped out
were significantly fewer in the intervention than in the
control group (28 and 48%, respectively; p\ 0.0003). No
significant differences were found between clinical and
metabolic characteristics of adherent compared to dropout
patients in any of the groups (data not shown).
Clinical and metabolic parameters
Patients in the CG showed no significant improvement of
their clinical and metabolic indicators during the 1-year
follow-up, except a nonsignificant decrease in total
cholesterol at 12 months and a transitory decrease in LDL-
c levels at 6 months (Table 1). Conversely, in the IG,
diastolic blood pressure, HbA1c, and all lipid fractions
decreased significantly at 6 months with either sustained or
further improvement at 12 months (Table 1). This group
also showed a small but nonsignificant decrease in BMI
values.
The magnitude of the significant decreases in DBP, gly-
caemia, HbA1c, total and LDL-cholesterol, and TG levels
attained values of -4.6 mmHg, -17.9 mg/dL (-0.99 mmol/
L), -14.9 mg/dL (-0.39 mmol/L), -9.2 mg/dL (-0.24
mmol/L), and -25.7 mg/dL (-0.29 mmol/L), respectively.
Both groups showed a significant increase in the per-
centage of people at the goal for systolic blood pressure
and total cholesterol, but this increase was larger in the IG
(Table 2).
Pattern of drug prescriptions
The above-mentioned improvement was not associated
with significant changes in drug treatment of hypergly-
caemia, blood pressure, and dyslipidemia, except a sig-
nificant decrease in monotherapy with oral antidiabetic
agents (Table 3).
A comparable percentage of people with dyslipidemia or
hypertension was in treatment in the CG at either the basal
or 12-month control (Table 4). A similar prescriptive sit-
uation was observed in people with hypertension in the IG.
Conversely, at the 12-month control, the percentage of
treated patients with dyslipidemia increased significantly in
the latter group. This value was significantly higher than
the percentage in the CG.
Annual eye and cardiovascular evaluation
Control of micro- and macroangiopathic impact of diabetes
improved significantly in the intervention group (around
100%) compared with the control group (75%) (Table 5).
Discussion
In our previous report on DIAPREM, we demonstrated that
care provided to our population with T2D and associated
CVRF at the primary care level was not effective enough to
prevent development and progression of chronic compli-
cations of the disease [20]. This concept was based on
HbA1c levels and other indicators of clinical and metabolic
control, also the annual frequency of chronic complication
evaluation, and the absence of systematic clinical records
as well as inadequate drug prescription. We assumed that
unfortunately, this poor provision of care was a common




occurring at the primary care level of a developing country.
Supporting this concept, two recent reviews analysed the
situation of attainment of treatment targets in people with
T2D and concluded that a large proportion of them failed to
reach glycaemic targets due to a combination of factors,
mainly poor adherence to treatment prescription and clin-
ical/prescription inertia from healthcare team members
[23, 24]. Further, Blondel et al. mentioned that this con-
dition that favours the development and progression of
chronic complications results from impaired attitudes,
perceptions, and behaviours of healthcare providers, in
particular frequent delays in the prescription of appropriate
interventions to achieve glycaemic targets. These authors
concluded that a better understanding of these factors
would facilitate implementation of suitable strategies to
assist healthcare team members to prescribe more timely
treatment to control blood glucose level.
On account of the above-mentioned evidences of
worldwide and local poor quality of care provided to
people with T2D, we call for urgent implementation of
effective care strategies to overcome these problems;
simultaneously, we have also decided to initiate this
implementation at the primary care level and with general
practitioners (GPs) and nurses, since they represent the first
Table 1 Clinical and metabolic outcomes
Parameters Results p value
Basal After 6 months After 12 months A B
Control group
Male 32% (81) –
Age (years) 55.2 ± 9.91 (81)
BMI (kg/m2) 34.9 ± 11.5 (77) 33.4 ± 8.3 (74) 34 ± 7 (80) 0.31 0.60
SBP (mmHg) 129.9 ± 17.6 (81) 130.8 ± 17.7 (80) 126.8 ± 15.1 (81) 0.68 0.06
DBP (mmHg) 79.9 ± 10.6 (81) 79.3 ± 10.3 (80) 78.2 ± 9.5 (81) 0.48 0.20
Glycaemia (mg/dL) 153.4 ± 58.5 (80) 156.1 ± 61.4 (81) 146.3 ± 46.5 (81) 0.6 0.33
HbA1C (%) 7.76 ± 2 (81) 7.66 ± 1.7 (81) 7.5 ± 1.2 (81) 0.6 0.24
(mmol/mol) 61 ± 21.9 60 ± 18.6 58 ± 13.1
Creatinine (mg/dL) 1.2 ± 1.7 (67) 0.9 ± 1 (63) 1.1 ± 1.3 (72) 0.65 0.32
Proteinuria (mg/dL) 2.8 ± 6.7 (21) 0.6 ± 0.8 (11) 0.35 ± 0.3 (11) 0.12 0.57
Total cholesterol (mg/dL) 194.7 ± 43.9 (78) 188.5 ± 48.4 (80) 185 ± 42 (80) 0.28 0.058
HDL-c (mg/dL) 48.1 ± 15.9 (71) 48.5 ± 10.5 (72) 47.1 ± 18.3 (72) 0.95 0.67
LDL-c (mg/dL) 118.1 ± 39.1 (70) 108.5 ± 33.7 (74) 119 ± 36.1 (72) 0.01 0.98
Triglyceride (mg/dL) 160 ± 77.4 (78) 166.2 ± 88.6 (74) 149.7 ± 79.6 (76) 0.38 0.38
Intervention group
Male 35% (111) – –
Age (years) 55.2 ± 9.2 (111)
BMI (kg/m2) 33.1 ± 6.8 (108) 32.9 ± 6.6 (108) 32.3 ± 6.8 (110)
SBP (mmHg) 126.4 ± 15.8 (111) 126.6 ± 13.4 (111) 124.7 ± 11.6 (110) 0.90 0.22
DBP (mmHg) 80.7 ± 10.8 (111) 77.5 ± 9.7 (111) 77.8 ± 9.4 (110) 0.001 0.006
Glycaemia (mg/dL) 161 ± 70 (111) 150 ± 53 (110) 143.1 ± 51 (111) 0.03 0.02
HbA1C (%) 7.65 2.1 (111) 7.22 ± 1.6 (111) 7.18 ± 1.4 (111) 0.01 0.004
(mmol/mol) 60 ± 23 55 ± 17.5 55 ± 15.3
Creatinine (mg/dL) 1.6 ± 2.3 (100) 1.29 ± 1.8 (99) 1.9 ± 2.5 (108) 0.20 0.30
Proteinuria (mg/dL) 0.8 ± 3 (47) 0.5 ± 1 (42) 0.7 ± 1.4 (54) 0.92 0.80
Total cholesterol (mg/dL) 196.9 ± 46.3 (108) 184.5 ± 34.2 (110) 182 ± 36 (111) 0.002 0.001
HDL-c (mg/dL) 49.1 ± 21.9 (105) 45 ± 10 (107) 45.3 ± 9.7 (110) 0.04 0.07
LDL-c (mg/dL) 117 ± 38.1 (104) 105.9 29.3 (106) 107.8 ± 30.9 (110) 0.01 0.05
Triglyceride (mg/dL) 201.2 ± 141 (105) 181 ± 105 (109) 175.5 ± 99 (111) 0.03 0.05
Values are mean ± standard deviation (SD). Number of cases in parentheses. BMI body mass index, SBP systolic blood pressure DBP diastolic
blood pressure, FBG fasting blood glucose, eGFR estimated glomerular filtration rate, HDL-c HDL-cholesterol, LDL-c LDL-cholesterol. p values




scenario that receives people with diabetes and CVRF who
request disease management [25]. Outcomes of the 1-year
DIAPREM implementation showed that, in the interven-
tion group, we significantly improved faulty diabetes care
processes and reversed undesirable care outcomes.
In the intervention group, the dropout rate decreased
significantly to almost half the rate recorded in the
control group and at the same time also significantly
increased the ophthalmological and cardiovascular
annual controls. These changes were associated with
significant and sustained improvement in HbA1c, blood
pressure values, and serum lipid profile without marked
changes in drug prescriptions. Since we have applied a
‘‘multistrategic approach to improve quality of care’’, all
these changes could be ascribed to different factors
which we will try to disaggregate in order to provide a
reasoned explanation.
One of these factors might be the inclusion of the call
centre to remind patients of their programmed control
visits; others might be the systematic record of clinical,
Table 2 Percentage of people who achieved treatment target values of clinical and metabolic parameters
Parameters Control Intervention p
Basal (%) 12 months (%) p* Basal (%) 12 months (%) p*
SBP\ 130 mmHg 46 68 0.04 52 84 0.00 0.009
DBP\ 80 mmHg 72 74 0.72 68 77 0.1 0.69
BP\ 130/80 mmHg 55 59 0.63 62 73 0.08 0.04
Glycaemia\ 100 mg/dL 16 14 0.63 19 10 0.056 0.43
HbA1c\ 7% 41 36 0.517 45 57 0.08 0.004
Cholesterol\ 200 mg/dL 51 69 0.024 57 76 0.004 0.31
Triglyceride\ 150 mg/dL 51 63 0.13 44 55 0.1 0.26
SBP systolic blood pressure, DBP diastolic blood pressure, BP blood pressure, * Basal versus 12 months (Chi-squared test).  Chi-squared test
(control vs. intervention at 12 months)
Table 3 Type of treatment
Treatment Control Intervention p
Basal n (%) 12 months n (%) p* Basal n (%) 12 months n (%) p*
Hyperglycaemia
Only LSC 1 (1) – – –
Treated with insulin or OAD 80 (99) 81 (100) – 111 (100) 111 (100) – –
Monotherapy 24 (30) 21 (26) 0.11 49 (44) 41 (37) 0.047 0.10
Combined OAD (2 or more) 21 (26) 21 (26) 0.75 31 (28) 31 (28) 0.79 0.75
Insulin ? OAD (1 or more) 27 (33) 29 (36) 0.37 24 (22) 33 (30) 0.09 0.34
Insulin 9 (11) 10 (12) 0.08 7 (6) 6 (5) 0.22 0.08
Hypertension
Only LSC 5 (7) 6 (8) 0.78 5 (5) 2 (2) 0.4 0.10
Treated with antihihypertensive 67 (93) 68 (92) – 91 (95) 99 (98) – –
Monotherapy 29 (43) 30 (44) 0.93 47 (52) 42 (43) 0.29 0.86
2 antihihypertensives 27 (40) 27 (40) 0.76 27 (29) 37 (37) 0.12 0.71
3 or more 11 (17) 11 (16) 0.51 17 (19) 20 (20) 0.71 0.50
Dyslipidemia
Only LSC 28 (47) 18 (33) 0.14 30 (36) 16 (17) 0.004 0.02
Treated with statins 32 (53) 36 (67) – 53 (64) 76 (83) – –
Monotherapy 30 (94) 30 (83) 0.95 51 (96) 63 (83) 0.99 0.97
2 statins 2 (6) 6 (17) 0.95 2 (4) 13 (17) 0.99 0.97
Proportions of cases in parentheses. LSC lifestyle changes, OAD oral antidiabetic drug. * Basal versus 12 months (Chi-squared test).  Chi-




metabolic, and treatment data with the corresponding
feedback form for the physician–nurse care team. In this
regard, Posadzki et al. [26] in their Cochrane revision
concluded that appointment reminders sent by telephone
can improve attendance rates and adherence to medications
or tests. Systematic patient records and feedback have also
been shown to exert a positive impact on programme
outcomes [27].
In each participating primary care centre of the inter-
vention group, we have also created an interactive, trained
physician–nurse team in which each member takes care of
a fixed number of patients for their yearly control and
treatment follow-up. In this context, combined team
approach interventions have been reported to be more
effective than single intervention targeting single primary
or community care professionals in improving metabolic
control of people with diabetes [28]. A team approach in
which trained physicians and nurses provide care man-
agement to people with diabetes at the primary care level
has also been shown to significantly improve care out-
comes [29]. Additionally, the sequential physician–nurse
duet care increases time devoted to each patient, without
affecting total number of patients attendance thus opti-
mizing use of time.
Training of physicians and nurses was certainly an
important component of our programme, and current data
support our previous positive experience with its imple-
mentation [30, 31].
Our multistrategic approach has facilitated access to
regular HbA1c measurement, and this initiative has been
shown to improve diabetes management at the primary care
level in developing countries such as South Africa [32].
Similar success was reported in remote Australian indige-
nous communities [33].
Finally, our approach to care of people with T2D and
CVRF also included some aspects of the care providing
process not frequently considered an important conditioner
of its quality, particularly at the primary care level. This
specific point is based on the assumption that achieved
outcome depends on medical technology but also on
whether what is currently known as ‘‘good’’ medical care
has been properly applied. We have also considered the
structure, administrative, and related processes that support
care provision, availability, and adequacy of facilities and
equipment; the qualifications of medical staff and their
organization as well as the administrative structure and
programme operation of our primary care units. A detailed
description of all these aspects and their impact on care
quality was already published in 2005 by Donabedian [34].
In order to test whether the significant clinical and
metabolic changes recorded in the Intervention Group
could have clinical significance, we have compared the
Table 4 Frequency of
hypertension and dyslipidemia
treatment
Treatment Control Intervention p
Basal % (n) 12 months % (n) p* Basal % (n) Annual % (n) p*
Dyslipidemia
No treated 51 (33) 52 (31) 46 (42) 26 (26)
Treated 49 (31) 48 (29) 0.99 54 (49) 74 (75) 0.012 0.01
On target 13 (4) 21 (6) 12 (6) 23 (17)
Under target 87 (27) 79 (23) 0.79 88 (43) 77 (58) 0.16 0.94
Hypertension
No treated 7 (5) 8 (6) 5 (5) 3 (3)
Treated 93 (67) 92 (68) 0.76 95 (91) 97 (98) 0.63 0.36
Target 39 (26) 44 (30) 38 (35) 47 (46)
Under target 61 (41) 56 (38) 0.60 62 (56) 53 (52) 0.36 0.89
Number of cases in parentheses. * Basal versus 12 months (Chi-squared test).  Chi-squared test (control
vs. intervention at 12 months)
Table 5 Frequency of annual
micro- and macroagiopaties
performance
Parameter Control Intervention p
Basal 12 months p* Basal 12 months p*
Eye test 63.8 % (72) 75.3 (77) 0.128 48 (%) (102) 100 (%) (105) 0.000 0.000
CV evaluation 49.3 % (77) 68.9 (77) 0.013 59.5 (%) (97) 98.1 (%) (105) 0.000 0.000
Number of cases in parentheses. CV cardiovascular. * Basal versus 12 months (Chi-squared test).  Chi-




magnitude of such changes with data reported in the lit-
erature. For that purpose, we took advantage of the sys-
tematic review and meta-analysis reported by Tricco et al.
[35] on the effectiveness of quality improvement (QI)
strategies on diabetes care, particularly assessing its impact
on glycated haemoglobin (HbA1c), and other cardiovas-
cular risk factors indicators. The result of such comparison
showed that except for the changes observed in SBP, every
outcome recorded in DIAPREM was larger than those
reported in the literature for the 12-month follow-up per-
iod. It must be stresses that none of our baseline data was
as high as those considered by Tricco et al., to render larger
outcomes differences.
In brief, implementation of our multistrategic diabetes
care programme—a combination of systemic changes,
education, consistent patient registry, and disease manage-
ment—has significantly improved patient’ adherence, qual-
ity of care, and treatment adherence; these changes were
associated with high motivation of the healthcare team par-
ticipating members, as well as the support of local health
authorities. Even though we did not quantify healthcare team
members motivation, they continuously manifested such
attitude through permanent expressions of their satisfaction
with their participation in the DIAPREM programme. All
together, they have led to significant improvement in clinical
and metabolic care indicators and optimization of human and
economic resources regularly available at the primary care
level. These simple and low-cost interventions yielded
appreciable improvement in diabetes and associated CVRF
control. Consequently, healthcare authorities must be aware
of these results and endeavour to replicate the model in
countries/regions with restricted health budgets in order to
alleviate the heavy burden that T2D imposes on the public
health budget, the community and, most of all, on the people
suffering from this disease.
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